secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcellx, Inc. (ACLX)
CIK:        0001786205
Form:       8-K
Filed at:   2023-12-08T23:59:59+00:00
Accession:  0001193125-23-291800
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcellx anito-cel Phase 1 shows 100% ORR, 76% CR; median PFS 28 months at 26.5 mo follow-up
--------------------------------------------------------------------------------

- 100% ORR (38/38) with 76% achieving CR/sCR; median PFS estimated at 28 months with 26.5 mo median follow-up.
- Safety: no grade ≥3 CRS, one grade 3 ICANS; no delayed neurotoxicity or parkinsonian symptoms reported.
- All 38 patients were triple-refractory; 68% penta-refractory; 63% had ≥1 high-risk clinical feature.
- Upcoming oral presentation at ASH on Dec 11; company webcast with expert panel same day.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1786205/000119312523291800/0001193125-23-291800-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1786205/000119312523291800/d626117d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-291800

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer